Tenaya Therapeutics, Inc.
TNYAHealthcare|Biotechnology|US
$0.36
+0.04 (+13.99%)
DCF Value
$0.57
Tangible Book / Share
$0.24
Cash / Share
$0.30
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05836259 Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM | Hypertrophic Cardiomyopathy | P1P2 | Recruiting | 30 | Open-label | — |
| NCT06228924 Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC | Arrhythmogenic Right Ventricular Cardiomyopathy | P1 | Recruiting | 15 | Open-label | — |
| NCT05112237 Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | Cardiomyopathy | Active | 200 | — | — | |
| NCT06311708 Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) | Arrhythmogenic Right Ventricular Cardiomyopathy | Recruiting | 200 | — | — |